Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.30 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.30 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.30 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6289830 | 0.73 | TSHR (0.36) | TSHRALDH1A1KCNN4MEN1KMT2A | |
| SCHEMBL28246803 | 0.71 | TSHR (0.35) | TSHRALDH1A1KCNN4MEN1KMT2A | |
| Biphenyl SCHEMBL27328558 | 0.67 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL3961409 | 0.64 | — | — | |
| SCHEMBL7894960 | 0.62 | TSHR (0.35) | TSHRACHE | |
| SCHEMBL28199155 | 0.61 | KDM4E (0.35) | ALDH1A1ACHE | |
| Naphthalene SCHEMBL7719483 | 0.58 | CYP2A6 (0.67) | TSHRALDH1A1KCNN4 | |
| SCHEMBL24689945 | 0.56 | TAAR1 (0.35) | TSHRALDH1A1ACHE | |
| SCHEMBL146928 | 0.56 | TSHR (0.53) | TSHRALDH1A1HTTACHE | |
| SCHEMBL30096503 | 0.56 | TAAR1 (0.35) | TSHRALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692149-B1 | METHOD FOR PRODUCING ORTHOMETALATED AND ORTHOSUBSTITUTED AROMATIC COMPOUNDS | SOLVIAS AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| US-7435840-B2 | Method for producing orthometalated and orthosubstituted metallocenes | SOLVIAS AG (CH) | 2008-10-14 | — | — | US | disclosed |
| US-20070149796-A1 | Ortho-functionalized mono- and diphosphino- ferrocenes, bisindenylferrocenes and ruthenocenes and their borane complex intermediates; valuable ligands for metal complexes serving as catalysts for, e.g. enantioselective hydrogenations | SOLVIAS AG (CH) | 2007-06-28 | — | — | US | disclosed |
| EP-1692149-A2 | METHOD FOR PRODUCING ORTHOMETALATED AND ORTHOSUBSTITUTED AROMATIC COMPOUNDS | Solvias AG (CH) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005056566-A2 | METHOD FOR PRODUCING ORTHOMETALATED AND ORTHOSUBSTITUTED AROMATIC COMPOUNDS | SOLVIAS AG (CH) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149796-A1 | Ortho-functionalized mono- and diphosphino- ferrocenes, bisindenylferrocenes and ruthenocenes and their borane complex intermediates; valuable ligands for metal complexes serving as catalysts for, e.g. enantioselective hydrogenations | BCL3, ORC3, BBC3 | TSHR 3700/4885ALDH1A1 4406/4885KCNN4 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.